2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.21 Serum Tumor Markers in Metastatic Oncogene-Driven Lung Adenocarcinoma

Pdf Summary

This study investigates the role of serum tumor markers in patients with metastatic oncogene-driven lung adenocarcinoma, specifically focusing on those with different driver mutations and the impact of tyrosine kinase inhibitor (TKI) therapy. Conducted at the University of Colorado Cancer Center, the study included 17 patients treated between 2014 and 2024. These patients received TKI treatment as their first line of therapy, and their serum tumor markers were regularly monitored until disease progression was detected via radiographic imaging.<br /><br />The study population consisted of 17 participants; 6 had ALK mutations, while 11 had EGFR mutations. The majority were white (82%), and the median age at diagnosis was 69 years. Various sites of metastasis were documented, with bone and brain being the most frequent. Treatment responses varied, but a notable 82% of patients showed a partial response to TKI therapy, with no complete responses reported. Different TKIs were used according to their mutations, including Osimertinib and Crizotinib.<br /><br />The results indicated that tumor markers decreased in most patients during TKI therapy, suggesting a favorable treatment response. All patients had elevated marker levels at the start of treatment, and before disease progression, there was typically a 10% increase in these markers, hinting at their potential as early indicators of disease progression. The decrease in markers was observed in both ALK and EGFR mutation groups.<br /><br />This study underscores the potential role of serum tumor markers as biomarkers for monitoring disease status and treatment response in lung adenocarcinoma patients with specific driver mutations undergoing TKI therapy. It provides a foundation for further research on optimizing treatment strategies based on serum tumor marker trends.

Asset Subtitle

Urs Weber

Keywords

serum tumor markers

metastatic lung adenocarcinoma

driver mutations

tyrosine kinase inhibitor

ALK mutations

EGFR mutations

Osimertinib

Crizotinib

treatment response

biomarkers